Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

A number of other brokerages have also commented on ACRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Canaccord Genuity Group began coverage on shares of Aclaris Therapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $11.33.

Aclaris Therapeutics Trading Down 0.5%

ACRS stock opened at $4.39 on Friday. The stock has a market capitalization of $613.81 million, a price-to-earnings ratio of -7.57 and a beta of 0.87. Aclaris Therapeutics has a 12-month low of $1.74 and a 12-month high of $6.60. The firm’s 50-day moving average price is $5.73 and its two-hundred day moving average price is $4.97.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. Equities analysts predict that Aclaris Therapeutics will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Aclaris Therapeutics during the second quarter worth about $53,096,000. Rock Springs Capital Management LP increased its stake in shares of Aclaris Therapeutics by 0.4% during the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock valued at $16,772,000 after purchasing an additional 18,909 shares in the last quarter. Braidwell LP increased its stake in shares of Aclaris Therapeutics by 26.1% during the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock valued at $11,333,000 after purchasing an additional 443,232 shares in the last quarter. Palo Alto Investors LP bought a new position in shares of Aclaris Therapeutics during the second quarter valued at approximately $8,535,045. Finally, Kalehua Capital Management LLC purchased a new position in shares of Aclaris Therapeutics during the first quarter valued at approximately $6,871,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company’s research programs have centered on small-molecule treatments designed to address inflammatory and autoimmune conditions, including dermatologic and rheumatologic diseases.

Aclaris’ lead investigational program is zunsemetinib (ATI-450), an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being evaluated for potential use in inflammatory conditions such as rheumatoid arthritis and psoriasis.